Cytomegalovirus glycoprotein vaccine (GlaxoSmithKline)

N/A

Report date: 2024/08/30 20:00:41

Base Information

Drug NameCytomegalovirus glycoprotein vaccine (GlaxoSmithKline)

Drug Alias NameGSK Biologicals' recombinant CMV gB vaccineGSK-1492903A

ClassificationVaccines > Biological material > Viral vaccineVaccines > Vaccine type > Combination vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCytomegalovirus Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsCytomegalovirus Infections

Other Information

ATC CodeN/A